Patents by Inventor Susan M. Freier

Susan M. Freier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of SMAD7 expression
    Patent number: 10517889
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting SMAD7 expression, which may be useful for treating, preventing, or ameliorating a disease associated with SMAD7.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: December 31, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Huynh-Hoa Bui
  • Modulators of PCSK9 expression
    Patent number: 10517953
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting PCSK9 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PCSK9.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: December 31, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Susan M. Freier
  • ANTISENSE COMPOUNDS TARGETING GENES ASSOCIATED WITH FIBRONECTIN
    Publication number: 20190382760
    Abstract: The present invention provides compounds comprising oligonucleotides complementary to a fibronectin transcript. Certain such compounds are useful for hybridizing to a fibronectin transcript, including but not limited to a fibronectin transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the fibronectin transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with fibrosis. In certain embodiments, such compounds are used to treat one or more symptoms associated with renal fibrosis.
    Type: Application
    Filed: April 29, 2019
    Publication date: December 19, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Frank Rigo
  • COMPOSITIONS FOR MODULATING C9ORF72 EXPRESSION
    Publication number: 20190367916
    Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 mRNA and protein in an animal with C9ORF72 specific inhibitors. Also disclosed herein are compositions and methods of selectively inhibiting a C9ORF72 pathogenic associated mRNA variant by administering an antisense compound targeting the region beginning at the start site of exon 1A to the start site of exon 1B of a C9ORF72 pre-mRNA. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 specific inhibitors include antisense compounds.
    Type: Application
    Filed: January 15, 2019
    Publication date: December 5, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Frank Rigo, Priyam Singh
  • Modulators of APOL1 Expression
    Publication number: 20190359981
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting APOL1 expression, which may be useful for treating, preventing, or ameliorating a disease associated with APOL1.
    Type: Application
    Filed: May 21, 2019
    Publication date: November 28, 2019
    Inventor: Susan M. Freier
  • Modulation of signal transducer and activator of transcription 3 (STAT3) expression
    Patent number: 10479993
    Abstract: Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: November 19, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Susan M. Freier, Robert A. MacLeod, Youngsoo Kim
  • Methods and compositions for modulating apolipoprotein (a) expression
    Patent number: 10478448
    Abstract: Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or Lp(a). Certain diseases, disorders or conditions related to apo(a) or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The antisense compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: November 19, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Susan M. Freier, Marc Lim, Andrew Dibble
  • MODULATION OF LNC05 EXPRESSION
    Publication number: 20190343863
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of Inc05 in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a cancer in an individual.
    Type: Application
    Filed: December 1, 2017
    Publication date: November 14, 2019
    Applicants: Cold Spring Harbor Laboratory, Ionis Pharmaceuticals, Inc.
    Inventors: Allen Tingjin Yu, David L. Spector, Frank Rigo, Susan M. Freier, Jan Bermann, Carmen Berasain
  • Methods and compositions for modlating apolipoprotein (A) expression
    Patent number: 10472629
    Abstract: Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or Lp(a). Certain diseases, disorders or conditions related to apo(a) or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The antisense compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 12, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Susan M. Freier
  • ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF
    Publication number: 20190323013
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Application
    Filed: November 29, 2018
    Publication date: October 24, 2019
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Freier
  • Compositions for modulating C9ORF72 expression
    Patent number: 10443052
    Abstract: Disclosed herein are compositions and methods for reducing expression of C90RF72 mRNA and protein in an animal with C90RF72 specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C90RF72 specific inhibitors include antisense compounds. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration C90RF72 specific inhibitors include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: October 15, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • Allele specific modulators of P23H rhodopsin
    Patent number: 10426789
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP) by administering a P23H rhodopsin specific inhibitor to a subject. The present embodiments provided herein are directed to compounds and compositions useful for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP). In certain embodiments, P23H rhodopsin inhibitors provided herein are allele-specific antisense compounds targeted to a P23H mutant allele that are capable of selectively inhibiting expression of P23H rhodopsin mutant protein to a greater extent than wild-type protein.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: October 1, 2019
    Inventors: Susan F. Murray, Punit P. Seth, Michael L. McCaleb, Susan M. Freier, Priyam Singh
  • COMPOUNDS AND METHODS FOR MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION
    Publication number: 20190276832
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: October 23, 2018
    Publication date: September 12, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Susan M. Freier
  • MODULATION OF HUNTINGTIN EXPRESSION
    Publication number: 20190249177
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: February 8, 2019
    Publication date: August 15, 2019
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION
    Publication number: 20190247420
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN3 mRNA in a cell or animal, and in certain instances reducing the amount of Ataxin-3 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to prevent or ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include ataxia, neuropathy, and aggregate formation. Such neurodegenerative diseases include SCA3.
    Type: Application
    Filed: November 10, 2017
    Publication date: August 15, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Holly Kordasiewicz
  • MODULATORS OF DNM2 EXPRESSION
    Publication number: 20190241896
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting DNM2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DNM2.
    Type: Application
    Filed: January 15, 2019
    Publication date: August 8, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Huynh-Hoa Bui, Susan F. Murray, Brett P. Monia, Shuling Guo
  • MODULATION OF PREKALLIKREIN (PKK) EXPRESSION
    Publication number: 20190233827
    Abstract: Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.
    Type: Application
    Filed: September 7, 2018
    Publication date: August 1, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Huynh-Hoa Bui
  • MODULATORS OF GROWTH HORMONE RECEPTOR
    Publication number: 20190225970
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
    Type: Application
    Filed: December 27, 2018
    Publication date: July 25, 2019
    Inventors: Sanjay BHANOT, Susan M FREIER, Huynh-hoa BUI
  • Oligomeric compounds comprising bicyclic nucleotides and uses thereof
    Patent number: 10337007
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: July 2, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Eric E. Swayze
  • MODULATION OF GYS1 EXPRESSION
    Publication number: 20190194666
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a glycogen storage disease or disorder in an individual in need.
    Type: Application
    Filed: June 19, 2017
    Publication date: June 27, 2019
    Applicants: Ionis Pharmaceuticals, Inc., The Hospital for Sick Chlidren
    Inventors: Tamar R. Grossman, Susan M. Freier, Berge Minassian, Saija Ahonen